StreetInsider.com News Articles

Lunai Bioworks signs exclusive deal with Tanaist for Parkinson's research

Tue, 22 Sep 2026 09:21:34 -0400

Lunai Bioworks, Inc. (NASDAQ: LNAI) announced an exclusive worldwide license and collaboration agreement with Tanaist, Inc. to add human cellular phenotyping to its Parkinson's disease discovery platform, according to a company press release dated Sept. 22, 2026.

Under the agreement, Lunai has exclusive rights to Tanaist's cellular phenotyping technology in the Parkinson's disease field for programs based on Lunai's patient phenoclusters. The companies plan to evaluate whether Lunai's clinical and proteomic signatures can be reproduced across agreed Parkinson's cohorts and connected to measurable differences in human cellular biology.

Lunai previously analyzed longitudinal clinical data and more than 4,500 proteomic probes from more

Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement

Tue, 22 Sep 2026 09:20:00 -0400

Exclusive worldwide agreement adds human cellular validation to Lunai's AI-driven Parkinson's workflow, connecting patient-derived subtypes with disease mechanisms, biomarkers and therapeutic targets

SACRAMENTO, Calif., Sept. 22, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (Nasdaq: LNAI), a biology-first AI drug discovery company, today announced an exclusive worldwide license and collaboration agreement with Tanaist, Inc. that adds human cellular phenotyping to Lunai's growing

Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement

Tue, 22 Sep 2026 09:20:00 -0400

Lunai Bioworks shares AI chemical-risk screening study results

Wed, 16 Sep 2026 09:26:17 -0400

Lunai Bioworks, Inc. (Nasdaq: LNAI) released results from a technical case study conducted by its BioSymetrics subsidiary evaluating structure-based screening tools for chemical outputs generated by artificial intelligence systems, according to a press release dated Sept. 16, 2026.

The study focused on predicting acetylcholinesterase (AChE) inhibition directly from molecular structure. AChE is an established target of organophosphate nerve agents and other neurotoxic compounds. Using publicly available NIH Tox21 assay data, BioSymetrics evaluated 9,667 compound entries, separating training, validation, and test sets by chemical scaffold. The selected model achieved an area under the receiver operating characteristic curve of 0.88. At the reported

Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI

Wed, 16 Sep 2026 09:25:00 -0400

5.1-fold enrichment using NIH Tox21 data validates structure-based AChE screening as OpenAI and Anthropic highlight growing dual-use AI risks

SACRAMENTO, Calif., Sept. 16, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (Nasdaq: LNAI) ("Lunai" or the "Company") today shared results from a technical case study conducted by its BioSymetrics subsidiary, supporting the development of structure-based screening tools

Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI

Wed, 16 Sep 2026 09:25:00 -0400

5.1-fold enrichment using NIH Tox21 data validates structure-based AChE screening as OpenAI and Anthropic highlight growing dual-use AI risks

Lunai Bioworks expands naked short selling lawsuit to add six broker-dealers

Thu, 27 Aug 2026 09:28:46 -0400

Lunai Bioworks, Inc. (Nasdaq: LNAI) has filed a Second Amended Complaint in the U.S. District Court for the District of Delaware, naming six registered broker-dealers and two broker-dealer principals as defendants for the first time, according to a press release from the company.

The case, Civil Action No. 26-549-CFC, alleges securities fraud and market manipulation under Rule 10b-5, with the complaint centered on naked short selling practices.

The allegations in the complaint have not been proven, and the named defendants are presumed to have meritorious defenses unless determined otherwise by a court or jury.

Lunai Bioworks is a Delaware corporation headquartered in Sacramento,

Lunai Bioworks expands naked short selling lawsuit to add six broker-dealers

Thu, 27 Aug 2026 09:28:46 -0400

The case, Civil Action No. 26-549-CFC, alleges securities fraud and market manipulation under Rule 10b-5, with the complaint centered on naked short selling practices.

The allegations in the complaint have not been proven, and the named defendants are presumed to have meritorious defenses unless determined otherwise by a court or jury.

Lunai Bioworks is a Delaware corporation headquartered in Sacramento,

Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

Thu, 27 Aug 2026 09:27:00 -0400

Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5

WILMINGTON, Del. and SACRAMENTO, Calif., Aug. 27, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (Nasdaq: LNAI) ("Lunai" or the "Company") today announced the filing of its Second Amended Complaint naming six registered broker-dealers and two broker-dealer principals as defendants for the first time, in the U.S. District Court for the District of Delaware (Civil Action No. 26-549-CFC).

Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

Thu, 27 Aug 2026 09:27:00 -0400

Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5

Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

Thu, 27 Aug 2026 09:27:00 -0400

Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5

Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

Thu, 27 Aug 2026 09:27:00 -0400

Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5

Lunai Bioworks signs Parkinson's deal with BrainStorm Therapeutics

Tue, 04 Aug 2026 15:29:30 -0400

Lunai Bioworks Inc. (NASDAQ: LNAI) has signed a Master Collaboration Agreement with BrainStorm Therapeutics Inc. to develop a precision medicine approach to Parkinson's disease, according to a press release dated Aug. 4, 2026. The companies are targeting an initial data readout from the collaboration for the first half of 2027.

The agreement combines BioSymetrics Inc., Lunai's wholly owned subsidiary, with BrainStorm's patient-derived human midbrain organoid platform. BioSymetrics will contribute its Contingent AI patient-stratification technology, while BrainStorm will provide human translational validation using familial Parkinson's disease brain organoids and associated AI capabilities.

The collaboration is organized around four objectives: aligning clinically defined Parkinson's

Lunai Bioworks signs Parkinson's deal with BrainStorm Therapeutics

Tue, 04 Aug 2026 15:29:30 -0400

The collaboration is organized around four objectives: aligning clinically defined Parkinson's

Lunai Bioworks signs Parkinson's deal with BrainStorm Therapeutics

Tue, 04 Aug 2026 15:29:30 -0400

The collaboration is organized around four objectives: aligning clinically defined Parkinson's

Lunai Bioworks signs Parkinson's deal with BrainStorm Therapeutics

Tue, 04 Aug 2026 15:29:30 -0400

The collaboration is organized around four objectives: aligning clinically defined Parkinson's

Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027